Vaxcyte (NASDAQ:PCVX) Shares Purchased Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Cisneros purchased $1,001–$15,000 of Vaxcyte shares on July 16 in a Bank of America trust account, according to a congressional disclosure.
• Vaxcyte shares opened at $61.16, with a $9.1 billion market capitalization. The company recently reported a quarterly loss of $1.97 per share, beating analyst expectations of a $2.06 loss.
• Analysts maintain a “Moderate Buy” consensus and an average price target of $86, while Vaxcyte insiders sold 121,873 shares worth approximately $6.7 million during the latest quarter.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on July 16th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
• Purchased $1,001 - $15,000 in shares of Praxis Precision Medicines NASDAQ: PRAX on 7/30/2026.
• Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
• Sold $15,001 - $50,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 7/30/2026.
• Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $61.16 on Tuesday. The stock has a market capitalization of $9.10 billion, a PE ratio of -8.02 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $30.81 and a 1 year high of $65.00. The firm has a fifty day moving average price of $58.29 and a 200 day moving average price of $56.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same period last year, the firm posted ($1.22) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Wall Street Zen upgraded Vaxcyte from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Zacks Research upgraded shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Vaxcyte has a consensus rating of "Moderate Buy" and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the sale, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $53.00, for a total value of $530,000.00. Following the sale, the chief financial officer owned 104,395 shares in the company, valued at approximately $5,532,935. This represents a 8.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 121,873 shares of company stock worth $6,671,730. Insiders own 3.30% of the company's stock.

Institutional Investors Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC boosted its holdings in Vaxcyte by 4.0% in the 2nd quarter. Hsbc Holdings PLC now owns 4,151 shares of the company's stock valued at $241,000 after purchasing an additional 159 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock valued at $34,000 after buying an additional 184 shares during the period. Meeder Advisory Services Inc. lifted its stake in shares of Vaxcyte by 2.9% in the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company's stock valued at $484,000 after buying an additional 231 shares during the period. CWM LLC grew its position in Vaxcyte by 9.0% during the fourth quarter. CWM LLC now owns 2,840 shares of the company's stock worth $131,000 after buying an additional 234 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in Vaxcyte by 27.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company's stock worth $78,000 after buying an additional 291 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Vaxcyte

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.